Immunotherapy of pancreatic cancer - weal and woe

• Verfasst von: Bazhin, Alexandr V. [VerfasserIn]
• Verfasst von: Werner, Jens [VerfasserIn]
• Verfasst von: Karakhanova, Svetlana [VerfasserIn]
• Titel: Immunotherapy of pancreatic cancer - weal and woe
• Verf.angabe: Alexandr V. Bazhin, Jens Werner, Svetlana Karakhanova
• E-Jahr: 2016
• Jahr: November 2016
• Umfang: 2 S.
• Fussnoten: Gesehen am 04.05.2020
• Titel Quelle: Enthalten in: Translational cancer research
• Ort Quelle: Shatin : AME Publishing Company, 2012
• Jahr Quelle: 2016
• Band/Heft Quelle: 5(2016), 6, Seite S1295-S1296
• ISSN Quelle: 2219-6803
• DOI: doi:10.21037/tcr.2016.11.24
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1697020119

Abstract

We appreciated reading the commentary “Pancreatic ductal adenocarcinoma—a new hope?” of Irving and Lobo (1) on our recent paper in the British Journal of Cancer (2). Indeed, pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. At present, only multimodal treatment including surgical resection can prolong survival of patients with this disease (3). Therefore, new therapeutic approaches against PDAC are urgently needed. One new option is to apply immunotherapy for these patients. Immunotherapy possesses a bright spectrum of approaches: (I) passive immunotherapy includes a treatment of patients with monoclonal antibodies (specific immunotherapy) or checkpoint inhibitors (non-specific immunotherapy); (II) cancer vaccines and cellular therapy belong to the active immunotherapy as well as interferon treatment (non-specific immunotherapy).